Doceree today opened three new media channels to its clinical signal infrastructure, extending real-time physician intent data into connected television, LinkedIn and open programmatic buying for pharmaceutical advertisers in the United States.

In Short

Drug companies usually decide which doctors to advertise to by looking at prescription claims records, which arrive weeks after the prescription was actually written. Doceree is selling an alternative that watches what a physician is doing inside clinical software right now and uses that to trigger a TV ad, a LinkedIn post or a programmatic bid within days instead. If it works as described, the planning cycle for pharmaceutical media shifts from a monthly or quarterly rhythm to a daily one, and the value of a claims-built audience segment falls.

What Doceree put into market

The product carries the name Intent Powered HCP Suite, and according to Doceree it brings Connected TV, Social and Programmatic under a single orchestration layer. The company disclosed the availability at the opening of Fierce Pharma Week 2026, with the release datelined Short Hills, New Jersey, September 14, 2026. Access runs through Daily Command, which Doceree describes as its operating system for pharma commercialization.

Each of the three channels is driven by what the company calls Clinical Intent Signals. According to Doceree, these are real-time indicators of what a physician is deciding, drawn from the clinical workflow itself rather than reconstructed weeks later from claims.

The suite arrives after two earlier additions to the same stack. Care Sequence, according to Doceree, activates a brand across the moments of a patient encounter, running from the waiting room through to the pharmacy fill via point-of-care, email and text touchpoints that respond to live clinical signals. A digital out-of-home offering followed, placing signal-triggered screens in healthcare venues nationwide. Neither carries a disclosed activation date or performance figure in the current release, and the company characterises both as successful without publishing supporting numbers.

The latency argument

Doceree frames the product against a structural timing problem in pharmaceutical media planning. Most healthcare professional media is planned on claims data, which the company acknowledges is comprehensive. The objection is speed. A prescription written on a given day typically surfaces in a claims-derived audience several weeks later, after adjudication, aggregation and modeling have run their course.

By the time a segment built that way is switched on, according to Doceree, the clinical decision that justified the segment has already been made, and frequently remade.

Harshit Jain, MD, Founder and Global CEO of Doceree, put the mismatch in commercial terms. "The industry has accepted a strange bargain: it pays real-time prices for reach," he said, adding that the reach is then aimed using data several weeks old.

Jain also described the decay curve the product is built around. "Clinical intent has a half-life," he said, citing a physician's question about a therapy, a new diagnosis in the chart and a formulary check as moments that predict the next prescription and that fade within days.

That claim is the commercial hinge of the entire product. It is also, in the material supplied, an assertion rather than a published finding. No decay curve, half-life measurement or comparative test against claims-derived segments accompanies the release.

How the signals are assembled

The technical description is more specific than the framing. According to Doceree, Clinical Intent Signals are drawn from three sources: activity inside the electronic health record workflow, engagement with clinical content across a network the company puts at more than 2,000 medical publishers, and point-of-care interactions captured through a patented Triggers layer spanning more than 185 EHR and platform integrations.

Resolution is the second half of the architecture. Each signal is matched deterministically to a verified National Provider Identifier through ESPYIAN, which Doceree describes as its identity graph of more than six million healthcare professionals. The company states explicitly that the model uses no probabilistic lookalikes and no inferred audiences.

The distinction Doceree draws is between description and anticipation. Claims-based segments describe what a physician did. Clinical Intent Signals, according to the company, describe what a physician is considering, and they are available at the moment they occur.

Deterministic provider identity is not novel in this market, and the NPI has become the default key across competing platforms. What differs here is the trigger: rather than matching a stable list of physicians to inventory, the system fires on a discrete clinical event and then carries that event across channels.

Three channels, one clock

Connected television

CTV placements reach verified healthcare professionals on connected sets, with creative sequencing keyed to live clinical intent rather than static specialty or decile lists. The practical consequence Doceree describes is a shift in where money lands: spend concentrates on physicians whose signals are active in the current week, not the week a segment was constructed.

Decile lists have organised pharmaceutical targeting for decades, ranking prescribers by volume within a therapeutic category. Replacing that ranking with an activity trigger changes which physicians receive weight, and when.

Social

The social component delivers HCP-verified placements on LinkedIn. Doceree characterises the platform as the professional network where physicians engage with peers, institutions and clinical content. Frequency and messaging adjust as intent rises or resolves.

LinkedIn has been absorbing an expanding share of professional targeting infrastructure. Microsoft extended LinkedIn profile data into connected TV campaigns in May 2026, creating a third buy-side activation path alongside Amazon DSP and The Trade Desk, and added job seniority as a targeting dimension the following month. The platform also formalised agency competence through an organisation-level certification programme on May 6, 2026.

Programmatic

The programmatic layer applies Clinical Intent Signals at the bid level, across both Doceree's endemic publisher network and open exchange inventory. The stated effect is that programmatic spend follows the physician's clinical journey in real time rather than a fixed flight plan.

All three channels are planned, activated and measured from Daily Command, and run inside Care Sequence alongside point-of-care, email, RepTwin, text and digital out-of-home placements.

Doceree offers a worked sequence: a signal captured at the point of care can shape a CTV exposure that evening, a LinkedIn placement the next morning and a programmatic follow-up the day after, with each step measured back to the same verified physician and ultimately to the prescription.

Measurement and terms of availability

Kamya Elawadhi, Co-founder and President of Doceree, positioned the suite as the closing of a gap rather than a new capability. "Care Sequence and DOOH proved that when channels take their cue from the clinic instead of the calendar," she said, engagement and prescribing behaviour move together.

Elawadhi also addressed the budget concentration argument. "Intent Powered HCP Suite closes the loop for the channels where most of the budget sits," she said, arguing that brands no longer need one plan for reach and a separate plan for relevance.

That correlation claim, that engagement and prescribing behaviour move together, appears without a study, a client name or a measured lift figure attached. It is the kind of statement that determines whether a pharmaceutical brand reallocates budget, and the release supplies no evidence for it.

Availability is limited to pharmaceutical manufacturers and their agencies in the United States, effective today, through Daily Command. Clinical Intent Signals are also reachable via agency DSP integrations and managed service, which means a buyer already committed to another demand-side platform can access the data layer without moving activation.

Measurement runs through what Doceree calls its closed-loop attribution framework. The reporting includes signal-to-exposure latency alongside conventional reach and conversion metrics. That latency metric is the more interesting of the two. A product whose entire argument rests on timing has made the timing itself a reported number, which gives buyers something specific to audit. What the release does not specify is how latency is defined, at which point the clock starts, or whether the figure is independently verified.

Doceree will demonstrate the suite throughout Fierce Pharma Week at Booth #1001. Jain is scheduled to join Maria Menounos for a fireside conversation titled "What Was My Doctor Thinking? Inside the Moment a Prescription Gets Written" on September 15, from 11:45 a.m. to 12:10 p.m. at the Pennsylvania Convention Center in Philadelphia.

A market already reorganising around clinical signals

The competitive backdrop matters more than the individual product. Healthcare advertising technology has spent eighteen months moving toward deterministic provider identity and workflow-level triggers, and several vendors have arrived at similar conclusions independently.

StackAdapt brought self-serve NPI targeting to pharmaceutical advertisers on January 6, 2026, allowing list uploads, forecasting, segment creation and activation across connected TV, display, native, audio and video within a single interface, with daily impression-level reporting. DeepIntent followed in March with Helix, a HIPAA-compliant healthcare marketing cloud covering 3.7 million healthcare providers and 240 million patient lives.

The supply side moved next. In late May 2026, DeepIntent disclosed three point-of-care deals inside a single week, with OptimizeRx, epocrates and Lane4.io, together covering six EHR systems and 158,000 unique doctors and bringing NPI-level trigger-based messaging to that platform for the first time. The epocrates component opened an in-workflow clinical reference environment used by more than one million clinicians to programmatic buying, which had not previously been possible.

Expansion continued through the summer. DeepIntent built a live sports and events package for pharmaceutical buyers on June 9, 2026, graded on script lift and provider reach rather than engagement metrics, then routed Vistar Media's out-of-home and point-of-care screens into its buying interface on August 18. Agentic planning arrived alongside the media expansion: the company put a conversational planning layer into beta in June and opened it to all clients on September 10, 2026, four days before Doceree's disclosure.

Measurement rigour has been catching up in parallel. CheckedUp secured Media Rating Council accreditation for specialty waiting room television delivery in June 2026, the second firm to clear that bar in point-of-care.

Doceree's suite therefore lands in a category where the underlying ideas are contested rather than unfamiliar. The differentiator claimed is orchestration across owned and open channels from one command layer, and the breadth of integration count: more than 185 EHR and platform connections against the six systems disclosed in DeepIntent's May supply deals. Those two figures are not measured the same way, and a platform integration is not equivalent to an EHR system, so direct comparison would be misleading.

Where the budget is

Pharmaceutical money has been moving, and moving unpredictably. Prescription drug brands raised multiscreen television spend 53% in the six months after the Food and Drug Administration's September 2025 enforcement letters on deceptive drug advertising, spending $4.95 billion between October 2025 and March 2026 against $3.23 billion a year earlier, according to Video Advertising Bureau analysis of Nielsen Ad Intel data. The number of active prescription brands on television rose alongside the spend.

That response ran counter to expectation. Enforcement concentrated on digital and social placements, and brands responded by consolidating into a channel with decades of established regulatory precedent. United States healthcare digital advertising spending, meanwhile, has been projected to pass $20 billion in 2026, a figure StackAdapt cited when it brought NPI targeting to market in January.

Connected television and social sit inside that flow, which explains Elawadhi's reference to the channels where most of the budget sits. A signal layer that cannot touch CTV reaches a fraction of the money.

What the release leaves open

Several questions sit unanswered in the material. No client names, pilot results or benchmark figures appear. The identity graph is described at more than six million healthcare professionals without a stated source for the underlying records or a match-rate disclosure against the channels being activated. LinkedIn placements are described as HCP-verified, without specifying whether verification occurs through Doceree's graph, through LinkedIn's own professional data, or through a match between the two.

Nor does the release address the compliance question that governs this category. Provider-facing campaigns keyed to NPI describe clinicians in their professional capacity, which is the structural reason the model has expanded faster than patient-side targeting. Doceree's description of Care Sequence, however, spans patient encounters from waiting room to pharmacy fill, and the company's own positioning statement claims measurement of clinical intent for both physicians and patients. The release does not separate the two data flows or name the standard applied to the patient side.

Signal-to-exposure latency remains the metric worth watching. If Doceree publishes distributions rather than averages, buyers gain a way to test whether real-time means hours or days. Until then, the industry has a product built on an untested assertion about how quickly clinical intent decays, sold into a market where the competing method is slower but auditable.

Timeline

Summary

Who: Doceree, a healthcare marketing technology company headquartered in Short Hills, New Jersey, with Harshit Jain, MD, Founder and Global CEO, and Kamya Elawadhi, Co-founder and President, providing the named comment. The intended buyers are pharmaceutical manufacturers and their agencies in the United States.

What: Intent Powered HCP Suite, which extends Doceree's Clinical Intent Signals into Connected TV, Social on LinkedIn and open programmatic buying under a single orchestration layer. Signals are drawn from EHR workflow activity, engagement across more than 2,000 medical publishers and point-of-care interactions captured through a patented Triggers layer spanning more than 185 EHR and platform integrations, then resolved deterministically to a verified NPI through the ESPYIAN identity graph of more than six million healthcare professionals. Measurement runs through a closed-loop attribution framework reporting signal-to-exposure latency alongside reach and conversion metrics.

When: September 14, 2026, at the opening of Fierce Pharma Week 2026, with availability effective the same day. A demonstration runs throughout the week at Booth #1001, and Jain is scheduled for a fireside session on September 15 from 11:45 a.m. to 12:10 p.m.

Where: The United States, through Daily Command, with signal access also available via agency DSP integrations and managed service. The conference activity takes place at the Pennsylvania Convention Center in Philadelphia.

Why: Pharmaceutical healthcare professional media has been planned largely on claims data, which surfaces a written prescription several weeks later after adjudication, aggregation and modeling. Doceree argues that clinical intent decays within days, leaving claims-built segments aimed at decisions already made. Extending real-time signals to CTV, social and programmatic places the timing argument in the channels that hold the largest share of pharmaceutical media budgets, in a category where competing vendors have spent eighteen months building deterministic provider identity and workflow triggers of their own.